Novo hits back at rivals with cut-price Wegovy subscriptions
Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
Biogen swoops on Apellis with $5.6bn offer
In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.
Eli Lilly makes $7.8bn takeover play for Centessa
Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.
UCB brings first therapy for rare disease TK2d to EU
The EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
AZ considers filings for long-acting Strensiq follow-up
AstraZeneca's long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
6th mRNA‑Based Therapeutics Summit
Advancing mRNA's Therapeutic Potential to Combat All Diseases
Agentic AI is Ready. Most Pharma Organizations Are Not
Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey
The Industry’s Most Comprehensive End-to-End TCE Forum
The 8th T Cell Engager Therapeutics Summit is taking place June 23–25 in San Diego, CA,
The Evolution Summit Announces May 2026 Program for Clinical...
marcus evans announces The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida.
PHARMAP 2026: Where Pharma Meets Policy
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2026)